Telomir Pharmaceuticals submits IND to FDA for Telomir-1 in TNBC

elomir Pharmaceuticals announced the submission of an Investigational New Drug application to the U.S. Food and Drug Administration for its lead candidate, Telomir-1, for the treatment of advanced and metastatic Triple-Negative Breast Cancer. The IND submission includes data from completed IND-enabling pharmacology, toxicology, and manufacturing studies. Subject to IND clearance, the Company plans to initiate a Phase 1/2 clinical trial evaluating Telomir-1 as an oral monotherapy in patients with advanced or metastatic TNBC. Subject to IND clearance, Telomir plans to initiate its Phase 1/2 clinical trial in advanced TNBC and continue advancing biomarker-driven development strategies. In parallel, the Company is continuing to expand its preclinical program, including evaluation of Telomir-Zn in additional TNBC animal models and further characterization of its mechanism of action. The Company has submitted scientific manuscripts to peer-reviewed journals and plans to present data at scientific conferences, including the AACR Annual Meeting 2026.